Can a simple protein test predict heart trouble in breast cancer patients?
NCT ID NCT06443645
First seen Feb 04, 2026 · Last updated Jun 19, 2026 · Updated 17 times
Summary
This study looks at whether a protein called SGLT2 is linked to heart damage caused by a common type of breast cancer chemotherapy. Researchers will measure SGLT2 levels in blood and cells from 50 women with localized breast cancer before and after treatment. The goal is to find better ways to identify who is at risk for heart problems, so doctors can prevent them in the future.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST NEOPLASMS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centre Paul Strauss
RECRUITINGStrasbourg, France
Contact Email: •••••@•••••
Contact
Contact Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.